Drug intelligence / Profile preview

Gubenquyujiedu

Development stage: Unknown
Lead developer: Xiyuan Hospital
Administration: Oral

Overview

Gubenquyujiedu is a Traditional Chinese Medicine (TCM) herbal formula developed by the Xiyuan Hospital of the China Academy of Chinese Medical Sciences. It is primarily investigated for the treatment of chronic obstructive pulmonary disease (COPD), targeting both the acute exacerbation and remission phases. The formula is designed to improve activity endurance and clinical symptoms in COPD patients. Research suggests its mechanism may involve the modulation of inflammatory factors and specific microRNAs, such as miRNA-1 and miRNA-199a-5p, which are associated with muscle function and inflammatory responses in pulmonary diseases.

Other names: Gubenquyujiedu formulaGuben Quyujiedu

Targets

miR-1 (MicroRNA-1)miR-199a-5p (MicroRNA 199a-5p)

Beyond the preview

Go deeper on Gubenquyujiedu.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gubenquyujiedu.

Explore the full profile